



Cep 182

PATENT
Docket 100/488P1C2

#7
DF

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

) Group Art Unit: 1812

Anderson et al.

RECEIVED

) Examiner: M. Allen

DEC 10 1993

Serial No. 08/035,427

GROUP 1800

Filed: March 22, 1993

For: VARIANTS OF TISSUE PLASMINOGEN
ACTIVATORS AND COMPOSITIONS AND
METHODS FOR SAME

)
) I hereby certify that this correspondence is being
) 460 Point San Bruno Boulevard, San Bruno, California 94068-4990
) So. San Francisco, CA 94080-4990
) (415) 225-3218
) Commissioner of Patents and Trademarks, Washington,
) D.C., 20231

on 23 November 1993

(Date of Deposit)

TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(b)

Aida A. Miclat

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Name of Depositing Party

Aida Miclat

Signature of Depositing Party

23 November 1993

Sir:

Date of Signature

Your petitioner, Genentech, Inc., having a place of business at 460 Point San Bruno Boulevard, South San Francisco, California 94080-4990 in the county of San Mateo represents that it is the owner of the entire right, title, and interest in the invention disclosed and claimed in the above-identified application and is also the owner of the entire right, title, and interest in the invention disclosed and claimed in application U.S. Serial No. 07/894,213 filed 03 June 1992 for "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS WITH IMPROVED THERAPEUTIC PROPERTIES."

The assignment of the above-identified application was filed in the U.S. Patent and Trademark Office on 27 March 1990 (Reel 5277, Frame 0157). Your petitioner attests that said assignment was reviewed by the undersigned and verifies that said assignment transfers to petitioner the entire right, title and interest in the invention disclosed and claimed in said application.

The assignment of application U.S. Serial No. 07/894,213 was filed in the U.S. Patent and Trademark Office on 03 June 1992 (Reel 6173, Frame 0823). Your petitioner attests that said assignment was reviewed by the undersigned and verifies that said assignment transfers to petitioner the entire right, title and interest in the invention disclosed and claimed in said application.

08/035,427


Your petitioner hereby disclaims the terminal part of any patent granted on the above-identified application or on any application that is entitled to the benefit of the filing date of this application under 35 USC §120 that would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent granted on application U.S. Serial No. 07/894,213 and hereby agrees that if a patent is granted on application U.S. Serial No. 07/894,213, any patent granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on application U.S. Serial No. 07/894,213, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent granted on application U.S. Serial No. 07/894,213 in the event that such patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The Commissioner is authorized to charge the statutory fee of \$110.00 required for filing this Disclaimer to Deposit Account No. 07-0630. Please charge any deficiency or credit any overpayment to Account 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.



Stephen Raines

Vice President Intellectual Property

Dated:

64